Baker Department of Cardiometabolic Health Research

Learn about the Baker Department of Cardiometabolic Health research groups and their projects.

Atherothrombosis and Vascular Biology Group

Research Program Leader: Professor Karlheinz Peter

The Atherothrombosis and Vascular Biology Group is developing advanced biotechnological tools for molecular imaging and innovative therapy of atherosclerosis, thrombosis and inflammation.

Read more


Cardiac Hypertrophy Group

Research Program Leader : Associate Professor Julie McMullen

The Cardiac Hypertrophy Group is focused on better understanding heart enlargement through comparing models of health and disease.

Read more


Haematopoesis and Leukocyte Biology Group

Research Program Leader : Associate Professor Andrew Murphy

The goal of the Haematopoesis and Leukocyte Biology Research Group is to understand the pathways contributing to enhanced leukocyte production and altered function in the context of chronic diseases.

Read more


Lipid Metabolism and Cardiometabolic Disease Group

Research Program Leader : Associate Professor Anna Calkin

The Lipid Metabolism and Cardiometabolic Disease Group takes a systems genetics approach to unravel the mechanistic underpinnings of cardiometabolic disease. and identify novel therapeutic targets.

Read more


Metabolomics Group

Research Program Leader: Professor Peter Meikle

The goal of the Metabolomics Group is defining the relationships between lipid metabolism and cardiometabolic disease to advance diagnosis and treatment.

Read more


Molecular Imaging and Theranostics Group

Research Program Leader: Dr Xiaowei Wang

The Molecular Imaging and Theranostics Group is working towards more sensitive diagnosis using molecular imaging, targeted therapies free from side-effects and using novel theranostic approaches for cardiovascular diseases.

Read more


Molecular Metabolism and Ageing Group

Research Program Leader: Associate Professor Brian Drew

The goal of the Molecular Metabolism and Ageing Group is to identify the genetic and molecular underpinnings of cardiometabolic disorders and ageing, with the ultimate aim of manipulating these pathways for therapeutic benefit.

Read more